CSIMarket
 
Clene Inc   (CLNN)
Other Ticker:  
 
 
Price: $0.4068 $0.01 1.700%
Day's High: $0.42 Week Perf: -8.38 %
Day's Low: $ 0.38 30 Day Perf: -11.58 %
Volume (M): 638 52 Wk High: $ 1.27
Volume (M$): $ 260 52 Wk Avg: $0.66
Open: $0.40 52 Wk Low: $0.25



 Market Capitalization (Millions $) 43
 Shares Outstanding (Millions) 105
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -50
 Cash Flow (TTM) (Millions $) 10
 Capital Exp. (TTM) (Millions $) 1

Clene Inc
Clene Inc is a biopharmaceutical company that focuses on the development of treatments for neurodegenerative diseases, such as multiple sclerosis and amyotrophic lateral sclerosis (ALS). They specialize in the development of nanotechnology-based therapeutics that aim to enhance the body's natural ability to repair and regenerate damaged cells in the central nervous system. Clene Inc's approach involves using their proprietary platform, known as Nanocatalysis, to develop therapeutic solutions that target underlying disease mechanisms rather than simply addressing symptoms. Their goal is to provide innovative and effective therapies that can improve the quality of life for patients suffering from neurodegenerative diseases.


   Company Address: 6550 South Millrock Drive, Suite G50 Salt Lake City 84121 UT
   Company Phone Number: 676-9695   Stock Exchange / Ticker: NASDAQ CLNN
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clene Inc

Major Pharmaceutical Preparations Company Sees Revenue Fade in Fourth Quarter of 2023

Clene Inc. (Nasdaq: CLNN) recently reported its full year 2023 financial results, revealing weak orders and a substantial increase in losses. The company experienced a shortfall per share increase to $-0.05 from $-0.01, while revenue dropped by a significant -27.35% to $0.17 million compared to the previous year. These figures indicate a challenging period for Clene Inc.
In contrast, the company had seen a surge in revenue during the third quarter, with a growth rate of 57.407% from $0.11 million. However, the loss per share also increased during this period. Furthermore, for the financial fourth quarter of 2023, Clene Inc. recorded a net loss of $-10.173 million, a much larger figure than the $-1.054 million loss reported a year ago. These results demonstrate the difficult market conditions and operational challenges that Clene Inc. faced during this period.

Clinical Study

Clene's CNM-Au8 Treatment Shows Promising Results in Long-Term Extension Trials for Multiple Sclerosis and Amyotrophic Lateral Sclerosis

Published Thu, Feb 29 2024 1:00 PM UTC

Clene Inc. and its subsidiary, Clene Nanomedicine Inc., have presented clinical results from two long-term extension trials highlighting the potential of CNM-Au8, a novel drug compound aimed at improving mitochondrial health and protecting neuronal function in patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The results, presented at the ninth a...

Clinical Study

Clene's CNM-Au8 Treatment Shows Remarkable Enhancements in Vision and Cognition During Long-Term Extension of VISIONARY-MS Trial?

Published Mon, Jan 8 2024 12:00 PM UTC

Clene Inc., a clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and safeguarding neuronal function for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), has recently revealed ground-breaking findings from the long-term open label extension (LTE) of the VISIONARY-MS trial....

Clinical Study

Clene's CNM-Au8 Therapy Shows Promise in Reducing ALS Biomarkers and Prolonging Survival: Revolutionary Findings from HEALEY ALS Platform Trial

Published Thu, Dec 21 2023 12:00 PM UTC

Clene Reports Promising Results in the Treatment of ALS with CNM-Au8SALT LAKE CITY, Dec. 21, 2023 - Clene Inc. (Nasdaq: CLNN) and its subsidiary Clene Nanomedicine Inc., pioneers in the field of mitochondrial health and neuronal function preservation, have recently announced significant advancements in the treatment of amyotrophic lateral sclerosis (ALS) through their CNM-Au...

Product Service News

Pioneering Progress: Clene Nanomedicine's Novel Drug CNM-Au8 Shows Promise in Treating Neurodegenerative Diseases

Published Thu, Dec 14 2023 1:37 PM UTC


Capitalizing on decades of scientific research and technological advancements, Clene Inc., along with its wholly owned subsidiary Clene Nanomedicine Inc., has announced an exciting evolution in the fight against neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis (MS). This late-clinical stage biopharmaceut...






 

Clene Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Clene Inc does not provide revenue guidance.

Earnings Outlook
Clene Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com